Aurobindo Pharma Limited, through its wholly owned subsidiary Aurobindo Pharma USA Inc. has received approval from the US Federal Trade Commission to proceed with the acquisition of Lannett Company LLC. The transaction is valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, and is expected to close before the end of June 2026.
Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition will expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network.
Lannett's manufacturing site in Seymour, Indiana, has the capacity to scale production to approximately 4 billion doses annually, strengthening Aurobindo USA's domestic manufacturing footprint. This enhanced capacity aligns with US policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.
The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share. The acquisition is anticipated to generate cost efficiencies, SG&A synergies, and operational integration advantages. The deal will also enhance Aurobindo's portfolio with a differentiated pipeline of complex generics and controlled substances.
Aurobindo Pharma USA Inc. is a wholly owned subsidiary of Aurobindo Pharma Limited, an integrated global pharmaceutical company headquartered in Hyderabad, India. Aurobindo Pharma Limited develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.